Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780929 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL15218403 | 0.75 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ACACBCA12CA2 | |
| SCHEMBL15218404 | 0.75 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2ACACBCA12CA2 | |
| SCHEMBL16907684 | 0.73 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2ACACBCA12CA2 | |
| SCHEMBL9888689 | 0.71 | ADH1B (0.41) | ALDH1A1SMN1; SMN2ACACBCA12CA2 | |
| SCHEMBL9888750 | 0.71 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2ACACBCA12CA2 | |
| SCHEMBL21789783 | 0.71 | ADH1B (0.41) | ALDH1A1SMN1; SMN2ACACBCA12CA2 | |
| SCHEMBL13770845 | 0.70 | ALDH1A1 (0.35) | ALDH1A1ACACB | |
| SCHEMBL15218449 | 0.70 | ADH1B (0.48) | ALDH1A1SMN1; SMN2ACACBCA12CA2 | |
| SCHEMBL18434131 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231628-B1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | ALDH1A1 168/4885UTS2R 2661/4885SMN1; SMN2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.